Comparison of clinical characteristics of patients with PMF stratified by the presence of MK, complex karyotype without monosomies, and sole trisomy 8
| Variables . | MK (n = 17) . | Complex karyotype without monosomies (n = 24) . | Sole trisomy 8 (n = 21) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 62 (30–83) | 60 (42–73) | 66 (28–85) | .2 |
| Age > 65 y; n (%) | 7 (47) | 6 (26) | 11 (52) | .2 |
| Males, n (%) | 9 (53) | 14 (58) | 11 (52) | .9 |
| Median hemoglobin, g/dL (range) | 9 (6–11) | 10 (5–16) | 10 (7–13) | .3 |
| Median leukocyte count × 109/L (range) | 6 (2–46) | 10 (2–157) | 12 (2–142) | .8 |
| Median platelet count × 109/L (range) | 50 (6–522) | 97 (8–981) | 133 (16–684) | .2 |
| DIPSS risk group, n (%) | ||||
| Low | 0 | 1 (5) | 0 | .7 |
| Intermediate-1 | 6 (35) | 5 (21) | 8 (38) | |
| Intermediate-2 | 8 (47) | 15 (62) | 10 (48) | |
| High | 3 (18) | 3 (12) | 3 (14) | |
| Constitutional symptoms, n (%) | 7 (41) | 10 (42) | 7 (33) | .8 |
| Circulating blasts ≥ 1%, n (%) | 13 (76) | 20 (87) | 15 (71) | .4 |
| Hemoglobin < 10 g/dL, n (%) | 11 (65) | 14 (58) | 12 (57) | .9 |
| Leucocytes > 25 × 109/L, n (%) | 3 (18) | 6 (25) | 3 (14) | .6 |
| Platelets < 100 × 109/L, n (%) | 12 (71) | 13 (54) | 9 (43) | .2 |
| Leucocytes < 4 × 109/L, n (%) | 5 (29) | 5 (21) | 6 (29) | .8 |
| Palpable spleen > 10 cm, n (%) | 1 (33) | 9 (56) | 3 (23) | .2 |
| Splenectomy, n (%) | 3 (19) | 7 (30) | 4 (19) | .6 |
| JAK2V617F status, number tested (% positive) | 4 (100) | 6 (60) | 4 (67) | .3 |
| Transplanted, n (%) | 1 (6) | 0 | 1 (5) | .5 |
| Deaths, n (%) | 14 (82) | 21 (88) | 17 (81) | .8 |
| Leukemic transformations, n (%) | 5 (29) | 2 (8) | 1 (5) | .05 |
| Variables . | MK (n = 17) . | Complex karyotype without monosomies (n = 24) . | Sole trisomy 8 (n = 21) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 62 (30–83) | 60 (42–73) | 66 (28–85) | .2 |
| Age > 65 y; n (%) | 7 (47) | 6 (26) | 11 (52) | .2 |
| Males, n (%) | 9 (53) | 14 (58) | 11 (52) | .9 |
| Median hemoglobin, g/dL (range) | 9 (6–11) | 10 (5–16) | 10 (7–13) | .3 |
| Median leukocyte count × 109/L (range) | 6 (2–46) | 10 (2–157) | 12 (2–142) | .8 |
| Median platelet count × 109/L (range) | 50 (6–522) | 97 (8–981) | 133 (16–684) | .2 |
| DIPSS risk group, n (%) | ||||
| Low | 0 | 1 (5) | 0 | .7 |
| Intermediate-1 | 6 (35) | 5 (21) | 8 (38) | |
| Intermediate-2 | 8 (47) | 15 (62) | 10 (48) | |
| High | 3 (18) | 3 (12) | 3 (14) | |
| Constitutional symptoms, n (%) | 7 (41) | 10 (42) | 7 (33) | .8 |
| Circulating blasts ≥ 1%, n (%) | 13 (76) | 20 (87) | 15 (71) | .4 |
| Hemoglobin < 10 g/dL, n (%) | 11 (65) | 14 (58) | 12 (57) | .9 |
| Leucocytes > 25 × 109/L, n (%) | 3 (18) | 6 (25) | 3 (14) | .6 |
| Platelets < 100 × 109/L, n (%) | 12 (71) | 13 (54) | 9 (43) | .2 |
| Leucocytes < 4 × 109/L, n (%) | 5 (29) | 5 (21) | 6 (29) | .8 |
| Palpable spleen > 10 cm, n (%) | 1 (33) | 9 (56) | 3 (23) | .2 |
| Splenectomy, n (%) | 3 (19) | 7 (30) | 4 (19) | .6 |
| JAK2V617F status, number tested (% positive) | 4 (100) | 6 (60) | 4 (67) | .3 |
| Transplanted, n (%) | 1 (6) | 0 | 1 (5) | .5 |
| Deaths, n (%) | 14 (82) | 21 (88) | 17 (81) | .8 |
| Leukemic transformations, n (%) | 5 (29) | 2 (8) | 1 (5) | .05 |
DIPSS indicates Dynamic International Prognostic Scoring System.2